Abstract Library

#4537 The usefulness of circulating fibrosis markers in detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a potential serious fibrotic complication in patients with neuroendocrine neoplasms (NENs), affecting the heart valves. Early detection is crucial to avoid severe manifestations. NT-proBNP is suggested as an initial screening tool in detection of CHD; however, the value of NT-proBNP as a screening tool is questionable.

Conference:

Presenting Author: Lau T

Authors: Lau T, Angeli E, Oksjoki R, Rasmussen V, Genovese F,

Keywords: carcinoid heart disease, biomarker, fibrosis marker,

#4110 The role of fibrosis markers in predicting decline in renal function in patients undergoing PRRT

Introduction: Renal impairment due to renal fibrosis is a potential side effect in NET-patients undergoing Peptide Receptor Radionuclide Therapy (PRRT). Fibrosis markers are small collagen formation - and degradation fragments that are measurable in circulation at very early stages of fibrosis formation.

Conference:

Presenting Author: Lau T

Authors: Lau T, Bossen L, Rasmussen D, Karsdal M, Genovese F,

Keywords: PRRT, Biomarker, Fibrosis Marker,

#3880 Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium – Comparison of clinico-pathological and survival outcomes

Introduction: The role of peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment in patients with is still controversial, although recent experiences showed encouraging results in terms of oncological outcomes.

Conference:

Presenting Author: Genova L

Authors: Genova L, Andreasi V, Partelli S, Muffatti F, Battistella A,

Keywords: peptide receptor radionuclide therapy, prrt, neoadjuvant, surgery, yttrium, lutetium,

#3401 Characterising aggressive pulmonary carcinoids through integrative omics analysis

Introduction: Atypical carcinoids, and our recently identified supra-carcinoids (Alcala et al. 2019) belong to the pulmonary carcinoid (PCA) group of low grade lung neuroendocrine tumors. Little is known about the underlying biology of these tumors, nor why some patients are prone to metastatic disease and tumor recurrence. To date, molecular analysis of these tumors has been limited, particularly with regard to whole-genome sequencing (WGS).

Conference:

Presenting Author:

Authors: Sexton-Oates A, Di Genova A, Alcala N, Mangiante L, Voegele C,

Keywords: pulmonary carcinoid, genome, transcriptome, epigenome, characterisation,

#1938 Eleven Years Survival after Combined Treatment of Surgery, Ultrasound-Guided Radiofrequency Ablation of Liver Metastasis, CT Embolization Plus Somatostatin LAR in a Case with Atypical Carcinoid of the Lung

Introduction: The combination of different therapeutic methods has an important place in the treatment of patients with NET and liver metastasis, ineligible for radical surgery.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Genov J, Terziev I, Petrov I, Grosdinski L, Vladimirov B,

Keywords: atypical carcinoid of the lung, liver metastasis,